
    
      -  Evaluate the safety and tolerability of MEDI-538 at doses of 5, 10, or 15 Î¼g/m2/24h by
           continuous IV infusion for 4 or 8 weeks in adult patients with B-cell NHL not eligible
           for

        -  Determine the MTD of MEDI-538 administered by continuous IV infusion for 4 or 8 weeks in
           adult patients with B-cell NHL not eligible for curative therapy.
    
  